MELBOURNE, August 20, 2026, 09:02 AEST
- CSL finished Wednesday at A$166.48, gaining 5.49% on the day and 23.7% over two sessions.
- The surge increased market value by approximately A$14.5 billion since Monday’s close.
- The stock is currently trading 19.6% higher than the average analyst target set before the results.
CSL Limited ASX:CSL added roughly A$14.5 billion in market capitalisation across two sessions as investors overlooked a record statutory loss and concentrated on steadying earnings.
The biotechnology company finished Wednesday at A$166.48, gaining 5.49%. This followed a 17.25% jump on Tuesday after the release of its annual results. Trading volumes hit A$645.9 million, making it the most actively traded stock on Australia’s market.
The recent rebound has altered the immediate valuation outlook. CSL is currently priced 19.6% higher than the A$139.20 average target from an August 7 survey of 16 analysts. As a result, the consensus ahead of results indicates potential downside rather than upside.
| Share-price test | Value | Investor read-through |
|---|---|---|
| Monday close, calculated | A$134.61 | Base prior to results |
| Tuesday close | A$157.82 | +17.25% |
| Wednesday close | A$166.48 | +5.49% |
| Two-session move | +23.7% | Roughly A$14.5bn in value gained |
| Average analyst target | A$139.20 | 16.4% under Wednesday’s close |
Investors are distinguishing between accounting losses and ongoing cash profits. CSL posted a US$2.6 billion loss to shareholders following US$7.1 billion in pre-tax impairments. The underlying NPATA dropped 2% to US$3.1 billion.
| FY26 scorecard | Reported | Change / comparison |
|---|---|---|
| Revenue and other income | US$15.8bn | 1% lower at constant currency |
| Underlying NPATA | US$3.1bn | 2% lower |
| Statutory net result | US$2.6bn loss | US$3.0bn profit logged for FY25 |
| Pre-tax impairments | US$7.1bn | US$5.5bn recognised in second half |
| Operating cash flow | US$3.5bn | Exceeds underlying NPATA |
| Net debt / EBITDA | 1.8× | Does not include restructuring and impairments |
Interim CEO Gordon Naylor described FY26 as “a year of reset.” The transformation generated savings of around US$176 million, exceeding the initial target. This outcome underpinned guidance for underlying profit growth of approximately 5% in FY27.
The outlook remains cautious. Revenue is projected to stay largely unchanged at FY26 exchange rates. An additional A$1.1 billion buyback represents approximately 1.5% of Wednesday’s market capitalisation.
| Business | FY26 revenue | Constant-currency change | What matters next |
|---|---|---|---|
| CSL Behring | US$11.4bn | 1% decline | Immunoglobulin demand and plasma profit margins |
| CSL Vifor | US$2.4bn | Increase of 3% | FY27 sales forecast roughly 25% lower |
| CSL Seqirus | US$2.0bn | 8% decrease | US vaccination uptake and flu shot demand |
Behring remains the main driver of recovery. The immunoglobulin business stayed level at US$6.2 billion, while albumin sales dropped 17% to US$1.1 billion, mostly due to Chinese cost controls. ANDEMBRY, a new treatment for hereditary angioedema, generated US$240 million in its first full year.
Vifor is causing a more pronounced impact on earnings. CSL anticipates that revenue for the division in FY27 will decline by around 25%. Sales are pressured by generic iron alternatives, modifications to VELPHORO reimbursement, and the removal of TAVNEOS.
| Analyst snapshot | Recommendation | Target | Gap to A$166.48 |
|---|---|---|---|
| S&P Global consensus, Aug. 7 | Buy: 7; Hold: 9; Sell: 0 | A$139.20 average | −16.4% |
| UBS, June 10 | Buy | A$158.00 | −5.1% |
| Morgans, May 12 | Buy | A$147.59 | −11.4% |
| Bell Potter, Aug. 2 | Hold | A$120.00 | −27.9% |
| Jefferies, May 28 | Hold | A$108.00 | −35.1% |
| Citi, May 13 | Hold | A$110.00 | −33.9% |
The analyst table remains the central focus for short-term tension. Each listed published target is below Wednesday’s closing price. The upper range of the wider survey, at A$198.05, continues to represent a 19% potential upside.
CSL maintained its final dividend at US$1.62, keeping the total payout for the year steady at US$2.92. Shares will go ex-dividend on September 9, and the record date falls the following day.
Trading in Australia restarts at 10:00 AEST on Thursday. In the next week, changes to targets could take precedence over ongoing accounting discussions. Investors are also set to see if the buyback will handle profit-taking after shares rebounded by 23.7%.
Risks: The surge offers limited scope for another downgrade. Setbacks include Vifor’s slide, sluggish albumin prices in China, softer US vaccination trends, and ongoing search for a permanent chief executive, which could postpone the reset.
Related articles: ASX:CSL
CSL’s rebound outruns the old targets
The market is pricing a cleaner FY27 before brokers have caught up.
Price versus pre-results targets
FY26: cash earnings versus write-downs
Revenue engine
Behring supplies roughly 72% of group revenue. Vifor revenue is guided about 25% lower in FY27.
What the next week tests
- Broker revisions: all named pre-results targets sit below spot.
- Buyback support: the new A$1.1bn programme equals about 1.5% of market value.
- Profit quality: investors need stable Behring margins, not another accounting reset.
- Leadership: the permanent chief-executive search remains open.
Recommendation mix · 7 Aug snapshot
Risk gauge
Sources: TradingView, CSL FY26 results summary, S&P Global analyst poll and CSL investor calendar. Financial figures are in US dollars unless marked A$. Market data as of 19 Aug 2026, 16:10 AEST.
